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Research advances has led to an increased survival for childhood cancer and importantly, 
recognition of the quality of that survivorship. Unfortunately, adult survivors of childhood 
cancers often suffer an array of adverse health related side-effects arising from necessary 
treatment. A highly prevalent complication that occurs many years after cessation of 
treatment, is the long-term alterations in sensory perception. This is typically presented as 
pain as a young adult, with the number of patients reporting pain becoming an indeterminate 
complication.  Recent investigations present the development of rodent models that allow the 
exploration of causative factors that initiate childhood cancer survivorship pain. Here we 
provide an overview that highlights the significant burden that survivorship pain has upon 
paediatric cancer patients. 
  





Progressive advancement of clinical trials for research, improvements in clinical diagnosis and 
adjuvant treatment for childhood cancer, as well as centralisation of care to specialist units, 
have led to marked improvements in survival rates of childhood cancer. As a result, 76% of 
childhood cancer patients now live 10 years or more following diagnosis. Following on from 
the improved rate of survivorship, focus has now turned to understanding and identifying 
adverse health complications that arise due to their cancer and/or treatment, which in turn 
impairs quality of life in childhood cancer patients[1].  
 
Impact of Chemotherapy upon Childhood cancer survivors 
 
Chemotherapy is a primary cancer treatment that is cytotoxic to rapidly dividing cells, and in 
most cases does not discriminate between cancer cells and healthy somatic cells. As a 
consequence, cancer treatment inherently impacts upon crucial physiological systems that are 
required to function correctly for normal everyday life, and crucially these effects are exerted 
during the normal developmental trajectory of the child. The impact of this is that large 
proportions of childhood cancer survivors suffer from a multitude of differing health related 
side-effects due to their cancer treatment (84%[2]). Typical complications include cognitive 
impairments, anxiety, depression, fatigue, loss of motor coordination and nephropathy[3]. A 
consequence of this, is that chemotherapy not only impacts upon physiological systems that 
are key to ‘survival’ but also impairs the highly refined developmental processes that will define 
the integrity and functionality of these systems into adulthood. Ultimately impairing function 
later in life. This is now recognised, with chemotherapy induced complications afflicting 70% 
of childhood cancer survivors [2]. An important consideration is that chemotherapy induced 
adverse health side effects, increase in prevalence in later life  [1,2]). Indeed, 68% of childhood 
cancer patients whom are 5 to 14 years post cancer diagnosis describe suffering from a chronic 
condition. However, significantly this number increases to 77%, 85% and 88% at 15-24 years, 
25-36 and 40-49 years post-diagnosis, respectively [2]. Furthermore, the severity of these side 
effects are increasingly associated with those patients that were exposed to chemotherapy at 
a young age. It is now apparent that a large proportion of adult childhood cancer survivors are 
suffering health complications many years after the cessations of treatment. For example, 
~80% of childhood cancer patients suffer from cognitive impairment and fatigue in adulthood. 
These adverse health complications were found in childhood cancer survivors whom were 
diagnosed with cancer between 11 and 15 years old, with quality of life reported when these 
patients were 35 years of age old [3,4]. In many instances these complications may go 
undiagnosed or under-represented in many instances. 
 Chemotherapy induced pain in childhood cancer survivors 
 
A wide range of cytotoxic agents are used to treat childhood cancer[5], these include Platinum 
based therapies used for treatment of malignant brain tumours, neuroblastoma, 
hepatoblastoma, osteosarcoma and germ cell tumour [6], whilst vincristine is widely used in 
both leukaemia and solid tumours[7]. As highlighted these treatments not only damage cancer 
but also other physiological systems. It is widely accepted in adult cancer patients that 
chemotherapy impacts upon the somatosensory nervous system, with chemotherapy induced 
sensory neuropathy highly prevalent in adult cancer patients (indeed, upto 90% of patients are 
adversely affected [8]). This is typically demonstrated through the onset of chronic pain 
accompanied by hallmarks of sensory neurodegeneration inclusive of intra-epidermal nerve 
fibre degeneration [9,10]. These adverse effects are principally associated with the extremities 
of patients limbs, and continue for many months or even years after treatment has stopped [8]. 
To date this has almost exclusively been investigated in adult cancer patients whom have 
undergone cancer treatment. With regards childhood cancer patients, there is evidence that 
platinum based chemotherapy is detrimental to the sensory nervous system[11]. Platinum 
based treatments in children under 5 years of age, damages hearing in approximately 50% of 
patients, with damaged auditory systems less prevalent in older patients (5% in patients older 
than 15yrs old) whom undergo the same treatment [6,12]. Incidently, in young patients there 
is a precedence for a delay in presentation of symptoms[6]. This can be greatly debilitating as 
impaired hearing impacts upon the individuals speech and language development. 
Consequently, impairing the childs development hinders academic achievement, whilst also 
impeding sociality due to difficulties in communication [6,12,13]. This highlights that the 
sensory nervous system is susceptible to damage from chemotherapy treatment as well as 
long lasting complications, with instances whereby symptoms may not present until later in life.  
 
One of the biggest health burdens for society is pain [14] and unfortunately there is a great 
body of evidence now supporting that adult survivors of childhood cancer suffer from sensory 
complications in relation to pain development. Despite the understanding that chemotherapy 
leads to significant neurotoxicity in adults, this knowledge has not been applied to 
understanding how cancer treatments may impact upon the quality of survivorship in childhood 
cancer survivors. Until recently the effect that cancer treatment has upon the physiological 
systems responsible for modulating pain in childhood cancer patients has not been extensively 
investigated. It is now recognised that~50% Childhood cancer survivors attribute pain as an 
adverse side effect of their cancer treatment [11,15]. The onset of survivorship pain is 
attributable to platinum and vinca alkaloid based chemotherapy[16,17], frontline treatments for 
childhood cancer. It is important to note, that the prevalence (8-68%) of pain in childhood 
cancer patients is presented many years after the cessation of treatment (typically depicted as 
10-15 years post diagnosis [7,18]). In addition, cancer treatment associated pain is 
increasingly prevalent with increasing age [2], with childhood cancer survivors also more 
susceptible to dependence upon prescribed analgesia[11]. Furthermore, patients who were at 
higher risks of pain later in life were those children diagnosed with cancer at a younger age 
and therefore exposed to treatment at a younger age[11]. Unfortunately, a long-term adverse 
health affliction such as chronic pain greatly limits physical activity, therefore is detrimental to 
academic and societal experiences such as attending higher education or interacting with 
friendship groups. Childhood cancer survivors typically have poor academic performance in 
part this is likely due to debilitating effects of chronic impact of pain[11]. Chronic pain in these 
individuals is associated with increased levels of fatigue and sedate lifestyles as their ability to 
perform physical tasks is impaired [11]. As a consequence of this, societal isolation childhood 
cancer survivors also suffer mental health issues depicted by anxiety and depression which 
further enforces chronic pain[11].  
 
This work highlights a potential unmet clinical need that requires further investigation.  
Furthermore, there are no condition-tailored analgesics available for childhood cancer 
survivors[19] as analgesia is predominantly ineffective and/or cause adverse side effects in 
the long-term. These difficulties arise due to analgesic management being based upon other 
neuropathic pain conditions[20] and a complete lack of understanding to what causes chronic 
pain in adult survivors of childhood cancers.  
 
Mechanisms underlying childhood cancer survivorship pain 
 
It is recognised that in humans as well as in rodent models, chemotherapy damages[21,22] 
and subsequently causes chronic pain[24,25]. However, the vast majority of research to date 
has focussed upon adult chemotherapy induced sensory neuropathy[8,26]. This has provided 
a level of mechanistic understanding of peripheral sensory nerve afferent degeneration [27,28] 
and peripheral sensory neuronal sensitisation [23]. Understanding the mechanisms by which 
chemotherapy treatment can impair paediatric cancer patient quality of life through the onset 
of pain complications has, however,  remained elusive. Recent work by several groups has led 
to the development of rodent models [29,30] that allow researchers to investigate those 
mechanisms by which chemotherapy administered early in life, causes a delayed but lasting 
pain into adulthood. These tools provide researchers the facility to investigate key causative 
factors that contribute to the development of chemotherapy induced neuropathic pain in 
paediatric patients. In addition, providing a pre-clinical basis to allow evaluation of the efficacy 
of current and novel analgesic approaches to provide an informed decision of which analgesia 
should be introduced as frontline treatments for paediatric patients.  
 
The nociceptive neuroaxis and pain perception is still developing during infancy and greatly 
depends upon an infant’s environmental stressors and experiences[31,32]. Noxious insults 
early in life (such as chemotherapy) lead to chronic pain manifesting later in life[29,32]. 
Furthermore, sensory nerves, particularly pain detecting C fibre nociceptors, become 
sensitised[33,34], with sensory neurons possessing the capacity to become ‘primed’ therefore 
remaining active for the long term[35]. Despite this, it is still unknown how cancer treatment 
during childhood can affect pain mechanisms and quality of life in adulthood.  Administration 
of cisplatin[29]  or vincristine[30] early in a young rodents life (in the first 2 weeks of a rodents 
life) leads to chronic pain manifesting in adulthood in these rodents when compared to age 
matched controls. These observations were not restricted to either gender [30]. Interestingly 
cisplatin induces both mechanical and heat hyperalgesia[29], whereas vincristine only leads 
to the development of mechanical hypersensitivity[30]. These alterations in nociceptive 
behavioural outcomes were associated with no chemotherapy induced impairment upon motor 
coordination[30]. Furthermore, the manifestation of chemotherapy induced neuropathic pain in 
adults is typically associated with the degeneration of primary sensory nerve fibres, depicted 
by slowing of sensory nerve conduction velocity and loss of intraepidermal sensory nerve fibre 
(IENF) innervations [21]. Schappacher et al. highlighted a comparable pathology in the 
vincristine induced childhood cancer survivorship pain model, with a loss of Protein Gene 
Product 9.5 (PGP9.5) positive sensory nerve fibre skin innervations in the vincristine treated 
group when compared to age matched controls[30]. Similarly, Hathway et al. also highlighted 
degeneration of the IENF profile in the cisplatin treated experimental group[29]. Interestingly 
these histological pathological features in the paediatric models were observed at time points 
shortly after administration of the chemotherapeutic agent. Importantly, Hathway et al also 
observed IENF morphology at the termination of the study when pain had become established. 
Here aberrant growth of IENF profiles were observed in the cisplatin treated animals[29]. This 
is of importance as aberrant sensory nerve fibre growth is a hallmark of peripheral sensory 
neuronal sensitisation and chronic pain [36,37], providing interesting outcomes by which pain 
may manifest in paediatric patients. To support this, further work by Schappacher et al. has 
interrogated sensory nervous system electrical activity and functionality[38]. Overall 
conduction velocity of C and A fibre afferents were unchanged, but early life treatment with 
vincristine induces dorsal root ganglia sensitisation. This was depicted by increased evoked 
discharge and spontaneous firing, but solely in large and medium sized DRG sensory neurons 
as well as lamina I spinal cord projection neurons. Whilst interestingly small diameter DRG 
sensory neurons displayed reduced levels of activity.  These studies highlight how exposure 
of chemotherapy to young individuals greatly impacts upon the structural and functionality of 




Although there is still much to be learnt, our current understanding of survivorship pain in adult 
childhood cancer survivors has established the significance of this problem.  There is now a 
clear realisation of the negative impact pain has upon the quality of survival.   Furthermore, 
integral studies have begun to decipher the impact cancer treatment has upon paediatric 
patients in relation to somatosensory neurodegenerative processes and pain development. 
Such information provides clinicians with crucial information that needs to be considered when 








1. Ness KK, Hudson MM, Jones KE, Leisenring W, Yasui Y, Chen Y, Stovall M, Gibson TM, 
Green DM, Neglia JP, Henderson TO et al: Effect of temporal changes in therapeutic 
exposure on self-reported health status in childhood cancer survivors. Ann Intern 
Med (2017) 166(2):89-98. 
 
2. Phillips SM, Padgett LS, Leisenring WM, Stratton KK, Bishop K, Krull KR, Alfano CM, 
Gibson TM, de Moor JS, Hartigan DB, Armstrong GT et al: Survivors of childhood 
cancer in the united states: Prevalence and burden of morbidity. Cancer 
Epidemiology Biomarkers & Prevention (2015) 24(4):653-663. 
 
3. Clanton NR, Klosky JL, Li C, Jain N, Srivastava DK, Mulrooney D, Zeltzer L, Stovall M, 
Robison LL, Krull KR: Fatigue, vitality, sleep, and neurocognitive functioning in adult 
survivors of childhood cancer: A report from the childhood cancer survivor study. 
Cancer (2011) 117(11):2559-2568. 
 
4. Rach AM, Crabtree VM, Brinkman TM, Zeltzer L, Marchak JG, Srivastava D, Tynes B, 
Lai JS, Robison LL, Armstrong GT, Krull KR: Predictors of fatigue and poor sleep in 
adult survivors of childhood hodgkin's lymphoma: A report from the childhood 
cancer survivor study. J Cancer Surviv (2017) 11(2):256-263. 
 
5. Hsiao CC, Chiou SS, Hsu HT, Lin PC, Liao YM, Wu LM: Adverse health outcomes and 
health concerns among survivors of various childhood cancers: Perspectives from 
mothers. Eur J Cancer Care (Engl) (2018) 27(6):e12661. 
 
6. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P: Auditory late 
effects of childhood cancer therapy: A report from the children's oncology group. 
Pediatrics (2010) 125(4):e938-950. 
 
7. Ness K, Jones K, Smith W, Spunt S, Wilson C, Armstrong G, Srivastava D, Robison L, 
Hudson M, Gurney J: Chemotherapy-related neuropathic symptoms and functional 
impairment in adult survivors of extracranial solid tumors of childhood: Results 
from the st. Jude lifetime cohort study. Arch Phys Med Rehabil (2013) 94(8):1451-
1457. 
 
8. Paice JA: Chronic treatment-related pain in cancer survivors. Pain (2011) 152(3 
Suppl):S84-89. 
 
9. Mao-Ying QL, Kavelaars A, Krukowski K, Huo XJ, Zhou W, Price TJ, Cleeland C, Heijnen 
CJ: The anti-diabetic drug metformin protects against chemotherapy-induced 
peripheral neuropathy in a mouse model. PLoS One (2014) 9(6):e100701. 
 
10. Hu LY, Zhou Y, Cui WQ, Hu XM, Du LX, Mi WL, Chu YX, Wu GC, Wang YQ, Mao-Ying 
QL: Triggering receptor expressed on myeloid cells 2 (trem2) dependent microglial 
activation promotes cisplatin-induced peripheral neuropathy in mice. Brain Behav 
Immun (2018) 68(132-145. 
 
11. Lu Q, Krull KR, Leisenring W, Owen JE, Kawashima T, Tsao JC, Zebrack B, Mertens A, 
Armstrong GT, Stovall M, Robison LL et al: Pain in long-term adult survivors of 
childhood cancers and their siblings: A report from the childhood cancer survivor 
study. Pain (2011) 152(11):2616-2624. 
 
12. Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe 
M, Dall'Igna P, Hiyama E, Brichard B et al: Sodium thiosulfate for protection from 
cisplatin-induced hearing loss. N Engl J Med (2018) 378(25):2376-2385. 
 
13. Aronson DC, Weeda VB, Maibach R, Czauderna P, Dall'Igna P, de Ville de Goyet J, 
Branchereau S, Perilongo G, Brock P, Zsiros J, Semeraro M et al: Microscopically 
positive resection margin after hepatoblastoma resection: What is the impact on 
prognosis? A childhood liver tumours strategy group (siopel) report. European 
journal of cancer (2019) 106(126-132. 
 
14. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT: Prevalence of chronic pain in 
the uk: A systematic review and meta-analysis of population studies. BMJ Open 
(2016) 6(6):e010364. 
 
15. Alberts NM, Gagnon MM, Stinson JN: Chronic pain in survivors of childhood cancer: 
A developmental model of pain across the cancer trajectory. Pain (2018). 
 
16. Gilchrist LS, Marais L, Tanner L: Comparison of two chemotherapy-induced 
peripheral neuropathy measurement approaches in children. Support Care Cancer 
(2014) 22(2):359-366. 
 
17. Gilchrist LS, Tanner L: The pediatric-modified total neuropathy score: A reliable and 
valid measure of chemotherapy-induced peripheral neuropathy in children with 
non-cns cancers. Support Care Cancer (2013) 21(3):847-856. 
 
18. Khan R, Hudson M, Ledet D, Morris E, Pui C, Howard S, Krull K, Hinds P, Crom D, 
Browne E, Zhu L et al: Neurologic morbidity and quality of life in survivors of 
childhood acute lymphoblastic leukemia: A prospective cross-sectional study. J 
Cancer Surviv (2014) 8(4):688-696. 
 
19. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, 
Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J et al: Prevention and 
management of chemotherapy-induced peripheral neuropathy in survivors of 
adult cancers: American society of clinical oncology clinical practice guideline. J Clin 
Oncol (2014) 32(18):1941-1967. 
 
20. Kurita GP, Sjogren P: Pain management in cancer survivorship. Acta Oncol (2015) 
54(5):629-634. 
 
21. Vencappa S, Donaldson LF, Hulse RP: Cisplatin induced sensory neuropathy is 
prevented by vascular endothelial growth factor-a. American journal of 
translational research (2015) 7(6):1032-1044. 
 
22. Boehmerle W, Huehnchen P, Peruzzaro S, Balkaya M, Endres M: 
Electrophysiological, behavioral and histological characterization of paclitaxel, 
cisplatin, vincristine and bortezomib-induced neuropathy in c57bl/6 mice. Scientific 
reports (2014) 4(6370. 
 
23. Joseph E, Chen X, Bogen O, Levine J: Oxaliplatin acts on ib4-positive nociceptors to 
induce an oxidative stress-dependent acute painful peripheral neuropathy. The 
journal of pain : official journal of the American Pain Society (2008) 9(5):463-472. 
 
24. Park H, Stokes J, Pirie E, Skahen J, Shtaerman Y, Yaksh T: Persistent hyperalgesia in 
the cisplatin-treated mouse as defined by threshold measures, the conditioned 
place preference paradigm, and changes in dorsal root ganglia activated 
transcription factor 3: The effects of gabapentin, ketorolac, and etanercept. Anesth 
Analg (2013) 116(1):224-231. 
 
25. Joseph E, Levine J: Comparison of oxaliplatin- and cisplatin-induced painful 
peripheral neuropathy in the rat. The journal of pain : official journal of the 
American Pain Society (2009) 10(5):534-541. 
 
26. Flatters SJL, Dougherty PM, Colvin LA: Clinical and preclinical perspectives on 
chemotherapy-induced peripheral neuropathy (cipn): A narrative review. Br J 
Anaesth (2017) 119(4):737-749. 
 
27. Flatters SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced 
painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain (2006) 
122(3):245-257. 
 
28. Xiao WH, Zheng H, Zheng FY, Nuydens R, Meert TF, Bennett GJ: Mitochondrial 
abnormality in sensory, but not motor, axons in paclitaxel-evoked painful 
peripheral neuropathy in the rat. Neuroscience (2011) 199(461-469. 
 
29. Hathway GJ, Murphy E, Lloyd J, Greenspon C, Hulse RP: Cancer chemotherapy in 
early life significantly alters the maturation of pain processing. Neuroscience 
(2017). 
 
30. Schappacher KA, Styczynski L, Baccei ML: Early life vincristine exposure evokes 
mechanical pain hypersensitivity in the developing rat. Pain (2017) 158(9):1647-
1655. 
 
31. Fitzgerald M, McKelvey R: Nerve injury and neuropathic pain - a question of age. 
Exp Neurol (2016) 275 Pt 2(296-302. 
 
32. Schwaller F, Fitzgerald M: The consequences of pain in early life: Injury-induced 
plasticity in developing pain pathways. The European journal of neuroscience (2014) 
39(3):344-352. 
 
33. Hirth M, Rukwied R, Gromann A, Turnquist B, Weinkauf B, Francke K, Albrecht P, Rice 
F, Hägglöf B, Ringkamp M, Engelhardt M et al: Nerve growth factor induces 
sensitization of nociceptors without evidence for increased intraepidermal nerve 
fiber density. Pain (2013) 154(11):2500-2511. 
 
34. Hulse R, Wynick D, Donaldson L: Intact cutaneous c fibre afferent properties in 
mechanical and cold neuropathic allodynia. European journal of pain (2010) 
14(6):565. 
 
35. Ferrari LF BO, Levine JD.: Nociceptor subpopulations involved in hyperalgesic 
priming. Neuroscience (2010) 165(3). 
 
36. Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, 
Ghilardi JR, Kuskowski MA, Mantyh PW: Pathological sprouting of adult nociceptors 
in chronic prostate cancer-induced bone pain. The Journal of neuroscience : the 
official journal of the Society for Neuroscience (2010) 30(44):14649-14656. 
 
37. Jimenez-Andrade JM, Mantyh PW: Sensory and sympathetic nerve fibers undergo 
sprouting and neuroma formation in the painful arthritic joint of geriatric mice. 
Arthritis Res Ther (2012) 14(3):R101. 
 
38. Schappacher KA, Xie W, Zhang JM, Baccei ML: Neonatal vincristine administration 
modulates intrinsic neuronal excitability in the rat dorsal root ganglion and spinal 
dorsal horn during adolescence. Pain (2018). 
 
 
